Patrícia Silva, PhD, director of science content —

Novartis’ Ultibro Breezhaler provided noteworthy improvements in cardiac and lung function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation (overinflated lungs) when compared to placebo, a new research study found. The study reporting the findings, “Effect of lung deflation with indacaterol plus glycopyrronium on ventricular…

Using long-term inhaled corticosteroids to relieve inflammation in chronic obstructive pulmonary disease (COPD) could increase the risk of bone fractures, new research suggests. A study published in the journal CHEST, “Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture,” was conducted by researchers from McGill University…

A diet rich in fresh tomatoes and fruits, especially apples, slowed the natural decline of lung function over a 10-year period among former smokers, found a study by Johns Hopkins Bloomberg School of Public Health in Baltimore. In fact, these foods can help slow down the decline of lung function for…

Many COPD patients who have acute flare-ups are not taking part in pulmonary rehabilitation programs, a British study shows. The research, “Effects of Pulmonary Rehabilitation on Exacerbation Number and Severity in People With COPD,” was published in the journal CHEST. COPD flare-ups not only harm patients’ health but also…

A new study conducted in London suggests that exposure to air pollution is enough to counter the health benefits of exercise in adults age 60 or older regardless of whether they have chronic obstructive pulmonary disease (COPD), heart disease, or are healthy. These findings stem from one of two…

Propeller Health and Express Scripts recently signed an agreement to provide a novel digital respiratory care solution to help manage chronic obstructive pulmonary disease (COPD) and asthma. Propeller developed a digital solution that combines inhaler sensors with a proprietary software platform that can be used as…

The COPD therapy-development partners Theravance Biopharma and Mylan have submitted a New Drug Application for revefenacin (TD-4208) to the U.S. Food and Drug Administration. Revefenacin is a long-lasting mist. The partners designed it so that chronic obstructive pulmonary disease need to take it only once a day. The therapy is called…

Boehringer Ingelheim will host a live event on Facebook and Twitter on Nov. 15 — World COPD Day — to increase awareness about how people with chronic obstructive pulmonary disease (COPD) can improve their quality of life. This year’s World COPD Day is led by the Global Initiative for…

People with chronic obstructive pulmonary disease (COPD) will soon have new resources available to them following the partnership of the COPD Foundation, Jvion, Geisinger, and GSK to find new ways to promote patient health, avoid hospitalizations, and prevent readmissions after an inpatient stay. The venture will…

Researchers from the Imperial College London in England and the National University of Singapore (NUS) have identified a grape polyphenol, known as isorhapontigenin, which shows potential for suppressing lung inflammation caused by chronic obstructive pulmonary disease (COPD). The naturally-derived compound belongs to the family of polyphenols, which are found abundantly…